

PRESS RELEASE August 16, 2007

## **Invitation**

### **Presentation of Interim Report for January- June 2007**

Biovitrum, invites media and analysts to a press- and analyst meeting in Stockholm on Thursday August 23 in conjunction with the disclosure of the Interim Report for January-June 2007.

The report will be presented by CEO Martin Nicklasson and CFO Göran Arvidson.

#### **Press and analyst meeting in Stockholm:**

Time: Thursday, August 23 at 15.00 (CET)  
Venue: Grand Hôtel, conference room "Vapensalen"  
Coffee will be served.

The report is scheduled for publication at 08.30 (CET) the same day.

#### **Participation:**

To participate please register to Lotta Nerblad, e-mail [lotta@zoomvision.se](mailto:lotta@zoomvision.se) or telephone +46 8 21 10 60.

---

#### **Internet broadcast:**

A live broadcast from the presentation will be available on the Internet, August 23 at 15. 00 (CET): [www.biovitrum.com](http://www.biovitrum.com)

#### **Telephone conference call:**

You may also participate by telephone.

#### **Dial-in numbers:**

S: +46 8 566 363 29  
UK: + 44 203 043 24 36  
US : +1 866 458 40 87

The slide presentation from the conference will be available on [www.biovitrum.com](http://www.biovitrum.com/investor-relations/presentations) /investor relations/ presentations.

**For more information, please contact:**

**Biovitrum AB (publ)**

Martin Nicklasson, CEO

Phone: +46 8 697 20 00

[martin.nicklasson@biovitrum.com](mailto:martin.nicklasson@biovitrum.com)

Göran Arvidsson, CFO

Phone: +46 8 697 23 68

[goran.arvidson@biovitrum.com](mailto:goran.arvidson@biovitrum.com)

Anna Karin Källén, Vice President, Corporate Communications

Phone: +46 8 697 20 85, Mobile: +46 734 33 20 85

[annakarin.kallen@biovitrum.com](mailto:annakarin.kallen@biovitrum.com)

**About Biovitrum**

Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK 1.2 billion and 550 employees. Biovitrum is listed on the OMX Nordic Exchange in Stockholm since September 15, 2006. For more information see [www.biovitrum.com/](http://www.biovitrum.com/).